LY450139 Semagacestat

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：LY450139 Semagacestat	Purity：98% min
CAS NO：425386-60-3	Solubility：DMSO : ≥ 100 mg/mL (276.67 mM)
Molecular Formula：C₁₉H₂₇N₃O₄	Package：Package according to customer requirements.
Molecular Weight：361.435	Storage：Store at -20℃

Quality control

COA

Remarks

Semagacestat, also known as LY450139 or LY4501; was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Ãlan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed less well than the placebo, led to investigators being instructed to tell subjects to stop taking the drug.

Gamma-secretase Inhibitors Related Products:

RO4929097; Avagacestat; Dibenzazepine; LY-411575; Crenigacestat; DAPT (GSI-IX)

References

[1]. Mitani Y, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012 Feb 8;32(6):2037-50.

[2]. Elvang AB, et al. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. 2009 Sep;110(5):1377-87.